SRAX Inc (SRAX): SRAX cheat sheet https://www.barchart...

Golden Cross · 2018-03-13T03:24:58.1900000Z

SRAX cheat sheet https://www.barchart.com/stocks/quotes/SRAX/cheat-sheet

Play Episode

4min

Proactive - Interviews for investors

Charbone Hydrogen partners with ABB to develop 15 green hydrogen facilities in North America

Charbone Hydrogen Chief Operations Officer Daniel Charette joined Steve Darling from Proactive to announce the signing of a Memorandum of Understanding with ABB, marking a significant step toward scaling green hydrogen production across North America. The agreement outlines plans to develop up to 15 modular and scalable hydrogen production facilities over the next five years, targeting industries that currently rely on grey hydrogen, such as steelmaking and heavy industrial processes. Under the MoU, ABB will serve as Charbone’s preferred supplier for modular electrical substations (eHouses), providing design, engineering, fabrication, and testing. ABB will also assist in standardizing core engineering systems across Charbone’s project portfolio to enhance energy efficiency and reliability. Depending on project needs, ABB may also take on automation, electrification, and telecom roles. One of the first projects in this collaboration is Charbone’s flagship Sorel-Tracy facility, located near Montreal, Québec. Expected to be connected to the Hydro-Québec grid by Q2 2025, the facility will utilize hydroelectric power to run green hydrogen electrolyzers, creating a scalable model for future sites. Following this, Charbone’s next project will be in the greater Detroit area, a key hub for automotive manufacturing. This initiative aligns with the Government of Québec’s Green Hydrogen and Bioenergy Strategy, which aims to reduce petroleum consumption by nearly 1 billion liters annually by 2030. By promoting green hydrogen adoption in key industrial sectors, the province could cut greenhouse gas emissions by 4 megatons of CO₂ per year—equivalent to removing 1.2 million gasoline-powered vehicles from the roads. With its partnership with ABB and government-backed initiatives supporting clean energy, Charbone Hydrogen is positioning itself as a leader in North America’s transition to sustainable hydrogen solutions. #proactiveinvestors #charbonehydrogencorportion #tsxv #ch #ot

Proactive - Interviews for investors

Astral Resoures’ pre-feasibility study on track for June

Astral Resources NL (ASX:AAR) managing director Marc Ducler talked with Proactive about the latest gold recovery results from the Mandilla Gold Project in Western Australia. He shared insights into recent metallurgical test work at the Theia prospect, where 87% gravity recovery and 98% overall recovery were achieved within 24 hours. Ducler highlighted that these strong results support the upcoming mineral resource estimate and pre-feasibility study. The company is optimising the resource estimate using a A$3,500 gold price and current mining and processing cost assumptions. The updated resource model is expected within two weeks, with the pre-feasibility study targeted for release in the June quarter. Ducler also provided an update on Astral’s takeover of Maximus Resources, which has reached a 72% acceptance level. The acquisition adds 330,000oz to Astral’s resource base and provides future infrastructure opportunities. Additionally, the company has active drilling programs, including diamond drilling at Camp Man, an air core program at Feysville, and a 46-hole RC drilling campaign set to begin shortly. For more insights from Astral Resources, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates.

Proactive - Interviews for investors

Atlantic Lithium chairman Neil Herbert on Ewoyaa's path to production, lithium market outlook

Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) executive chairman Neil Herbert talked with Proactive's Stephen Gunnion about the company's strategy to bring the Ewoyaa Lithium Project in Ghana into production. Herbert acknowledged the recent downturn in lithium prices but emphasised the strong long-term demand driven by electric vehicle and battery storage growth. He highlighted Ewoyaa's position as a low-cost producer, making it attractive to off-takers looking for stable future supply. Discussing funding strategies, Herbert outlined a collaborative approach involving partners such as Piedmont Lithium, Sayona Mining, and Assore International. He also noted increasing interest from non-Chinese off-takers in Europe, the Middle East, and Asia. The Ghanaian government has shown strong support for the project, with mining lease ratification expected in the second quarter of the year. Herbert also discussed the project's high feldspar content, which could support Ghana’s ceramics industry, and touched on exploration potential in Ghana and Côte d'Ivoire. The company raised A$10 million to optimise Ewoyaa ahead of a final investment decision, expected in Q3 2025. Watch the full interview to learn more about Atlantic Lithium’s plans. Don’t forget to like, subscribe, and turn on notifications for more updates from Proactive! #AtlanticLithium #LithiumMining #EwoyaaProject #EVBatteries #BatteryMetals #MiningStocks #Investing #LithiumDemand #GhanaMining #MiningIndustry

Proactive - Interviews for investors

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Followers	3353
Posts	91190
Boards Moderated	7
Alias Born	10/05/2005

Volume:	-
Day Range:
Bid:	0.57
Ask:	0.5901
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SRAX Detailed Quote

Recent SRAX News

More SRAX News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SRAX News

Go Ad-Free